Pancreatic Cancer Research

ResearcherUniversity of Mississippi Medical CenterActive in the last 2 years

Seema Singh

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7188-3803; OpenAlex author ID A5115603189; NIH RePORTER profile ID 10099269. Sources: OpenAlex.

Their work

Papers
22 (first author 0, last author 4)
Trials
0
Grants
1
Labs led
1
Collaborators
19
Papers, trials and grants by year

2011: 2 papers · 2012: 1 paper · 2013: 1 paper, 1 grant · 2014: 1 paper · 2015: 3 papers · 2016: 3 papers · 2017: 2 papers · 2018: 1 paper · 2019: 1 paper · 2020: 3 papers · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper

Papers 22

  1. MYB and HIF1α crosstalk drives hypoxia-induced transcriptional reprogramming and adaptive signaling alterations in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2025.217916↗
  2. Mitochondrial Translocase TOMM22 Is Overexpressed in Pancreatic Cancer and Promotes Aggressive Growth by Modulating Mitochondrial Protein Import and Function. Co-author DOI 10.1158/1541-7786.mcr-23-0138↗
  3. MYB sustains hypoxic survival of pancreatic cancer cells by facilitating metabolic reprogramming. Co-author DOI 10.15252/embr.202255643↗
  4. Detection of mitochondrial DNA mutations in circulating mitochondria-originated extracellular vesicles for potential diagnostic applications in pancreatic aden… Co-author DOI 10.1038/s41598-022-22006-5↗
  5. Hypoxia alters the release and size distribution of extracellular vesicles in pancreatic cancer cells to support their adaptive survival. Co-author DOI 10.1002/jcb.29328↗
  6. Co-targeting of CXCR4 and hedgehog pathways disrupts tumor-stromal crosstalk and improves chemotherapeutic efficacy in pancreatic cancer. Co-author DOI 10.1074/jbc.ra119.011748↗
  7. Comprehensive Analysis of Expression, Clinicopathological Association and Potential Prognostic Significance of RABs in Pancreatic Cancer. Co-author DOI 10.3390/ijms21155580↗
  8. Exosomal markers (CD63 and CD9) expression and their prognostic significance using immunohistochemistry in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.21037/jgo.2018.07.02↗
  9. ETV4: an emerging target in pancreatic cancer. Last author DOI 10.18632/oncoscience.471↗
  10. Exosomes confer chemoresistance to pancreatic cancer cells by promoting ROS detoxification and miR-155-mediated suppression of key gemcitabine-metabolising enz… Co-author DOI 10.1038/bjc.2017.18↗
  11. Molecular Drivers of Pancreatic Cancer Pathogenesis: Looking Inward to Move Forward. Co-author DOI 10.3390/ijms18040779↗
  12. p-21 activated kinase 4 (PAK4) maintains stem cell-like phenotypes in pancreatic cancer cells through activation of STAT3 signaling. Last author DOI 10.1016/j.canlet.2015.10.028↗
  13. Deep sequencing and in silico analyses identify MYB-regulated gene networks and signaling pathways in pancreatic cancer. Co-author DOI 10.1038/srep28446↗
  14. MYB Promotes Desmoplasia in Pancreatic Cancer through Direct Transcriptional Up-regulation and Cooperative Action of Sonic Hedgehog and Adrenomedullin. Co-author DOI 10.1074/jbc.m116.732651↗
  15. Insights into the Role of microRNAs in Pancreatic Cancer Pathogenesis: Potential for Diagnosis, Prognosis, and Therapy. Co-author DOI 10.1007/978-3-319-23730-5_5↗
  16. MicroRNA-345 induces apoptosis in pancreatic cancer cells through potentiation of caspase-dependent and -independent pathways. Co-author DOI 10.1038/bjc.2015.252↗
  17. Gemcitabine triggers angiogenesis-promoting molecular signals in pancreatic cancer cells: Therapeutic implications. Co-author DOI 10.18632/oncotarget.3784↗
  18. p-21 activated kinase 4 promotes proliferation and survival of pancreatic cancer cells through AKT- and ERK-dependent activation of NF-κB pathway. Last author DOI 10.18632/oncotarget.2398↗
  19. An undesired effect of chemotherapy: gemcitabine promotes pancreatic cancer cell invasiveness through reactive oxygen species-dependent, nuclear factor κB- and… Co-author DOI 10.1074/jbc.m113.484576↗
  20. CXCL12/CXCR4 protein signaling axis induces sonic hedgehog expression in pancreatic cancer cells via extracellular regulated kinase- and Akt kinase-mediated ac… Last author DOI 10.1074/jbc.m112.409581↗
  21. MicroRNA-150 directly targets MUC4 and suppresses growth and malignant behavior of pancreatic cancer cells. Co-author DOI 10.1093/carcin/bgr223↗
  22. Honokiol arrests cell cycle, induces apoptosis, and potentiates the cytotoxic effect of gemcitabine in human pancreatic cancer cells. Co-author DOI 10.1371/journal.pone.0021573↗

Grants 1

  1. ETV4 in pancreatic cancer R03CA169829↗

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ajay P. Singh · 21 shared papers, 2011–2024 · strength 1.83
  2. Mohammad Aslam Khan · 11 shared papers, 2015–2025 · strength 1.55
  3. Shashi Anand · 5 shared papers, 2020–2025 · strength 1.03
  4. Kunwar Somesh Vikramdeo · 4 shared papers, 2022–2025 · strength 0.90
  5. Sanjeev K. Srivastava · 13 shared papers, 2011–2023 · strength 0.83
  6. Moh'd M. Khushman · 8 shared papers, 2016–2022 · strength 0.75
  7. Arun Bhardwaj · 13 shared papers, 2011–2019 · strength 0.67
  8. Santanu Dasgupta · 3 shared papers, 2020–2024 · strength 0.53
  9. Sachin Kumar Deshmukh · 3 shared papers, 2016–2023 · strength 0.37
  10. Ajay Pratap Singh · 1 shared paper, 2025 · strength 0.33
  11. Girijesh Kumar Patel · 4 shared papers, 2017–2020 · strength 0.32
  12. Shafquat Azim · 3 shared papers, 2016–2023 · strength 0.31
  13. Sumit Arora · 7 shared papers, 2011–2016 · strength 0.29
  14. Mary C. Patton · 3 shared papers, 2017–2020 · strength 0.29
  15. Mary Oluwadamilola Haastrup · 1 shared paper, 2024 · strength 0.23
  16. Nikhil Tyagi · 4 shared papers, 2014–2016 · strength 0.22
  17. Martin J. Heslin · 1 shared paper, 2022 · strength 0.16
  18. Marcus Chuan Beng Tan · 1 shared paper, 2019 · strength 0.07
  19. Gary Anthony Piazza · 1 shared paper, 2013 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.